Shares of Zoetis Inc. (NYSE:ZTS) have received a consensus recommendation of “Buy” from the nineteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $67.93.
Several equities research analysts have recently issued reports on ZTS shares. BMO Capital Markets set a $65.00 target price on Zoetis and gave the company a “hold” rating in a research report on Wednesday, October 25th. BidaskClub raised Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a report on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Finally, Jefferies Group reissued a “buy” rating on shares of Zoetis in a report on Friday, November 10th.
A number of hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC increased its stake in shares of Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after buying an additional 5,734,776 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Zoetis by 55.4% during the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after purchasing an additional 3,695,449 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after purchasing an additional 1,412,829 shares in the last quarter. AJO LP lifted its holdings in shares of Zoetis by 4,506.8% during the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock valued at $79,311,000 after purchasing an additional 1,243,826 shares in the last quarter. Finally, Thrivent Financial For Lutherans lifted its holdings in Zoetis by 642.7% in the second quarter. Thrivent Financial For Lutherans now owns 1,336,033 shares of the company’s stock valued at $83,342,000 after acquiring an additional 1,156,142 shares during the period. Hedge funds and other institutional investors own 93.33% of the company’s stock.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the business earned $0.52 EPS. The business’s revenue was up 8.5% on a year-over-year basis. equities research analysts forecast that Zoetis will post 2.37 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.58%. Zoetis’s payout ratio is currently 22.11%.
ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/zoetis-inc-zts-given-consensus-recommendation-of-buy-by-analysts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.